Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients.
about
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantationGene therapy in transplantation.Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathwayGene therapy in transplantation in the year 2000: moving towards clinical applications?Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2Dendritic cells, tolerance induction and transplant outcome.Dendritic cell control of tolerogenic responses.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Gene- and cell-based therapeutics for type I diabetes mellitus.DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice.Tolerance-inducing strategies in islet transplantationDendritic cells as promoters of transplant tolerance.Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus.Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Development of dendritic cell-based immunotherapy for autoimmunity.Dendritic cell-based therapy in Type 1 diabetes mellitus.Dendritic cell therapy for Type 1 diabetes suppression.Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.A self-immunomodulating myoblast cell line for erythropoietin delivery.Protective effects of Fc-fused PD-L1 on two different animal models of colitis.Role of NF-kappaB on liver cold ischemia-reperfusion injury.Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection.Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice.Cytotoxic T lymphocyte antigen 4 immunoglobulin modified dendritic cells attenuate allergic airway inflammation and hyperresponsiveness by regulating the development of T helper type 1 (Th1)/Th2 and Th2/regulatory T cell subsets in a murine model ofIslet/pancreas transplantation: challenges for pediatrics.Donor dendritic cells and recipient Kupffer cells in the induction of donor-specific immune hyporesponsivenessGeneration, Characteristics and Clinical Trials of Ex Vivo Generated Tolerogenic Dendritic Cells
P2860
Q21284774-D83BE1A8-6E68-47E3-A9AF-447D497E12ABQ33734501-99E0CE82-2614-4A9F-BAE8-B3E0BD939B1DQ33811694-33229A34-CEC7-419D-9C8E-079CA259C8DFQ33840985-5EA20FD3-4C9E-41A7-87B5-20FFBBCF6467Q34338355-79719277-408B-4323-8B68-5D94680DD645Q34353313-5C914706-ABAB-4BD9-9E76-537533A563F1Q34740521-B36BD1D0-3A1F-49E5-8187-BE64C9664323Q34982085-2279D4ED-4FBC-44FA-A791-8764B2D07958Q35116303-F09DF18B-A1CB-46A2-8B46-DA4C0CC39851Q35122170-714C136E-60B1-4285-93B2-70402DA475FEQ35843248-D01E95CE-778E-423F-917C-A258D1BDC571Q36004707-D53BD000-CD30-468F-987D-954F2AF4E670Q36425922-36811B5A-3631-45B6-AF61-511D0B86E2FEQ36897372-57190FA8-C527-4ED2-90E3-D74386F689A2Q36901406-DE854956-EDC4-4E5D-BFD8-BF09E8A78D97Q37701864-8E313162-9E5C-496D-9AC2-C367722AB2EEQ37754644-4E035EAB-2042-4919-90B4-869065A54ADEQ38059518-17682CEB-5781-4142-8D3B-8FD99F5F5E9EQ39946625-F1222CFD-BB67-4CE8-80D8-54F381882FAFQ40799718-D50ED823-84DB-4949-879B-2C428ED63689Q42214211-49A0BDE4-1CE4-403C-B0A8-72FA521D2442Q44180707-AAC276F3-11DB-496C-9106-12646CFA74E0Q44321933-4AC828EC-06B4-4494-B63F-9A1D08D765D0Q45858420-D7629E7D-DEEC-43CB-8F72-CF8AF2026AA4Q45879284-FE39803D-264D-4F3C-BA30-1DFA89923A45Q50521304-6FF3EAB0-4F82-426E-9A5D-71CAB02D8B81Q51006250-8AB7343C-0A25-486D-BD89-ADE0B3367D53Q56905361-9F8948BA-8B9F-43F4-86E3-2C552F38EA44Q57166377-20083159-0132-461A-A9B2-6D8010ACFE7A
P2860
Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@en
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@nl
type
label
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@en
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@nl
prefLabel
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@en
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@nl
P2093
P2860
P356
P1433
P1476
Adenoviral delivery of CTLA4Ig ...... ival in allogeneic recipients.
@en
P2093
A Gambotto
A W Thomson
C A Bonham
P D Robbins
P2860
P2888
P304
P356
10.1038/SJ.GT.3300862
P577
1999-04-01T00:00:00Z
P5875
P6179
1053451902